Please assess the completion status of the following clinical trial:

Trial Title: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Histologically or morphologically confirmed acute myeloid leukemia (AML), meeting 1 of the following criteria:~    * Relapsed or refractory AML after treatment with ≥ 1 prior conventional induction therapy~      * Patients in early first relapse must not have a matched donor available and/or be ineligible for allogeneic stem cell transplantation~   * Poor-risk AML, as defined by any of the following criteria:~      * Treatment-related AML, unless associated with favorable cytogenetics (e.g., inversion 16, t\[16;16\], t\[8;21\], t\[15;17\]), and ineligible for stem cell transplantation~     * Antecedent hematological disease (e.g., myelodysplastic syndromes, myelofibrosis, or polycythemia vera) that evolved to AML (≥ 20% blasts) and ineligible for stem cell transplantation~     * De novo AML (must be \> 70 years of age)~     * AML with unfavorable cytogenetics (e.g., abnormalities of chromosomes -7, -5, 7q-, or 5q-; complex \[≥ 3\] abnormalities; or abnormalities of 11q23, excluding t\[9;11\], t\[9;22\], inversion 3, t\[3;3\], and t\[6;9\]), regardless of age, and ineligible for allogeneic stem cell transplantation~ * High-risk myelodysplastic syndromes diagnosed by morphologic, histochemical, or cell surface marker criteria~    * Resistant or intolerant to chemotherapy~   * Ineligible for or unwilling to undergo immediate allogeneic stem cell transplantation~* Bone marrow index (i.e., percent cellularity × percent blasts) ≤ 40% at time of treatment~* No active CNS leukemia~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Bilirubin ≤ 1.5 mg/dL~* ALT and AST \< 2.5 times upper limit of normal~* Albumin ≥ 3 mg/dL~* Creatinine ≤ 1.5 mg/dL~* LVEF ≥ 50%~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 2 weeks after completion of study treatment~* No complicated medical or psychiatric problems that would preclude study compliance~* No concurrent serious uncontrolled infection or disseminated intravascular coagulation~* No myocardial infarction within the past 6 months~* No allergies to diphtheria toxin~* No requirement for oxygen~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No other concurrent antineoplastic drugs~* No concurrent radiotherapy~* No concurrent corticosteroids as antiemetics~* No concurrent hematopoietic growth factors (e.g., epoetin alfa, interleukin-11, filgrastim \[G-CSF\], or sargramostim \[GM-CSF\])~* No concurrent intravenous immunoglobins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SL-401 (Type: EXPERIMENTAL): Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete